.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ischemic stroke remains a leading cause of disability globally. Consequently, researchers are exploring novel therapeutic agents to mitigate brain damage. Recent evidence highlights the potential for leptin neuroprotection in stroke recovery. Leptin, primarily known for regulating appetite, acts as a potent signaling molecule in the central nervous system. A comprehensive systematic review of 17 preclinical studies involving 1,383 animals reveals that leptin administration significantly reduces brain injury.
Specifically, the hormone triggers several pro-survival signaling cascades. The analysis identified the PI3K/Akt and JAK/STAT3 pathways as critical drivers of these protective effects. These pathways help maintain cell viability by inhibiting apoptosis and reducing oxidative stress. Furthermore, leptin promotes neurogenesis and angiogenesis, which are vital for long-term functional recovery. Therefore, the hormone does not only prevent cell death but also supports the brain's natural repair mechanisms.
Notably, the meta-analysis demonstrated a significant reduction in infarct volume, with a standardized mean difference of -2.76. Beyond structural preservation, leptin also improves neurobehavioral outcomes. Animals treated with leptin showed enhanced motor coordination and sensory function. These findings suggest that leptin could provide a dual benefit by protecting tissue and improving quality of life. However, translating these rodent-based successes into human clinical trials remains the next major challenge for the scientific community.
While the preclinical data is robust, researchers must optimize delivery methods and dosage for humans. Identifying the therapeutic window is essential, as the timing of administration significantly impacts efficacy. Additionally, understanding how leptin interacts with existing therapies like thrombolysis will be crucial. Researchers are optimistic that metabolic hormones could eventually become a cornerstone of acute stroke management.
Leptin activates specific pathways, such as PI3K/Akt and JAK/STAT3, which prevent cell death and promote the growth of new blood vessels and neurons.
No, the current evidence is primarily based on preclinical animal models. Clinical trials are needed to confirm the safety and efficacy of leptin in humans.
Yes, meta-analyses show that leptin administration significantly reduces the volume of infarcted (damaged) brain tissue in rodent models of ischemia.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.
References
Behrouzifar S et al. Leptin-induced neuroprotection in ischemic stroke: a comprehensive systematic review and meta-analysis elucidating molecular pathways in preclinical animal models. Brain Inj. 2026 Feb 28. doi: 10.1080/02699052.2026.2636708. PMID: 41761843.
Amantea D et al. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: Effects on STAT3 phosphorylation. Neurobiology of Disease. 2011.
Avraham Y et al. Leptin induces neurogenesis and angiogenesis after stroke. PubMed. 2011.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research confirms that leptin significantly reduces brain infarct volume and enhances motor function recovery in animal models through key molecular pathway...
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
